Company to Host Conference Call Today, March 27, at 4:30pm ETBOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and ...

McDonald Criteria revisions around 30% of patients with atypical clinical symptoms or radiological-only presentation meet MS ...

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...

Similar to other recent studies, this Phase 2b study in CIDP begins with a non-placebo controlled run-in (Period 1), during which participants whose disease had worsened during standard of care ...

Chronic inflammatory demyelinating polyneuropathy (CIPD) can have a substantial impact on patients everyday life and, ...

The risk of developing MS and other demyelinating diseases is 3 times greater in individuals diagnosed with EBV-positive IM.

I foolishly was in a crowded indoor location and got COVID (for the third time). I thought about getting Paxlovid. But I figured, heck, I’m healthy and vaccinated; I’ll just tough it out. This turned ...

Almost without fail, a person will enter the examination room, make no introduction, and launch into a series of questions or ...